AI in Dentistry: Transforming Patient Care and more

By Audrey Liz Perez on Mar 12, 2025.

Introduction

Drug discovery used to take decades and millions of dollars. Now, artificial intelligence (AI) is changing that timeline—and what it means for patient care. You've probably heard about AI tools transforming healthcare, but artificial intelligence is also now identifying potential new medications in months, not years. AI-driven drug discovery utilizes machine learning to analyze vast biological datasets, identify promising drug targets, and predict molecular interactions, all with remarkable accuracy (Rehman et al., 2024).

Instead of the traditional trial-and-error approach, which can span decades, AI systems can efficiently process complex biological data, thereby reducing both development time and costs (Vora et al., 2023). These tools excel at analyzing intricate biological networks (Yadav et al., 2024), enabling pharmaceutical teams to identify compounds that may be effective, streamline chemical processes, and make informed decisions about which treatments to pursue.

What does this mean for healthcare? Faster access to new treatments, more targeted therapies, and potentially lower costs—all because AI is making drug development more precise and successful. More than speed, it's about getting better treatments to patients sooner.

Applications of artificial intelligence in drug discovery

AI methods are revolutionizing the approach to every stage of drug development, from early discovery to clinical trials. Here's how it's making an impact:

Target identification

AI helps you identify drug targets by analyzing massive datasets, like genomic, proteomic, and clinical data. Deep neural networks find patterns in this information, pinpointing disease-related genes or proteins.

Tools like DeepMind’s AlphaFold predict 3D protein structures (Desai et. al., 2024), aiding researchers in understanding target interactions. AI enhances target identification accuracy, reducing the time required for experimental validation by applying deep learning methods.

AlphaFold played a crucial role in accelerating COVID-19 research by enabling scientists to understand viral protein structures more quickly than traditional methods allowed.

Drug design and optimization

Generative AI, such as generative adversarial networks (GANs), can help design entirely new molecular structures or refine existing ones (Tripathi, 2022). These models predict bioactivity, toxicity, and pharmacokinetics, enabling the efficient optimization of leads.

The drug DSP-1181, created for OCD, was developed in just under a year using AI —a timeline unheard of in traditional drug development.

Virtual screening

With AI, you can run high-throughput virtual screenings on massive chemical libraries. Deep learning models predict how compounds will interact with biological targets (Javid et. al., 2025), helping you prioritize those with the best therapeutic potential and lowest toxicity.

Clinical trials

AI supports smarter clinical trial design by analyzing patient data to optimize participant selection (Chopra et al., 2023). This enhances diversity, improves trial outcomes, and accelerates timelines. AI can also monitor data in real time to help you adjust trial parameters dynamically.

Chemical synthesis

AI suggests efficient synthesis pathways for drug compounds, which helps you reduce cost and development time. It also recommends changes to improve scalability, a feature particularly useful when transitioning from lab research to large-scale production.

Prediction of drug properties

Early in development, AI can help you predict a drug’s toxicity, solubility, and stability. These insights reduce the risk of failure later in clinical trials. It’s a more informed way to focus your efforts on compounds with the best potential for success.

Based on all the information provided above, it would be helpful to provide examples of actual drugs that have been discovered through AI assistance/tools. Discuss if they were effective or not. Discuss at least 3 by making a new section for it.

Examples of AI-discovered drugs and their effectiveness

AI-assisted drug discovery is already producing real-world results. Here are three examples:

DSP-1181: Developed by Exscientia for OCD, this was one of the first drugs created using AI. It reached trials in under 12 months, a process that typically takes years. Clinical results are still pending, but the accelerated timeline is promising.
Baricitinib: Originally for arthritis, this drug was repurposed using BenevolentAI to treat COVID-19. It received emergency use authorization and helped reduce recovery time in hospitalized patients.
INS018_055: Designed by Insilico Medicine for idiopathic pulmonary fibrosis, this drug reached Phase I trials in just 18 months. Early data indicate potential, supporting the role of AI in accelerating development for complex conditions.

Benefits of using AI for drug discovery

AI brings measurable benefits to drug discovery, improving workflows, saving time, and leading to better outcomes.

Faster target identification

AI accelerates the identification of biological targets by quickly analyzing massive datasets, such as amino acid sequences and molecular structures (Jiang et. al., 2024). Unlike traditional methods, which rely on labor-intensive experiments, AI-driven approaches, such as structure-based drug discovery, predict target interactions with higher accuracy.

Automation of processes

From de novo drug design, to molecular screening and chemical synthesis, AI allows you to automate key steps. This reduces human error and gives you clearer, more reproducible results. With explainable AI, you can also understand why the model made certain recommendations, making your decisions more transparent and informed.

Lower research costs

AI reduces costs by minimizing unnecessary experimentation and helping you identify opportunities for repurposing. By uncovering new uses for existing drugs, you can avoid the cost of starting from scratch while still delivering innovation.

Enhanced predictive models

Utilizing deep learning and large language models, AI can predict molecular interactions and potential side effects. This helps you focus resources on the compounds most likely to succeed, reducing the risk of costly trial failures.

Tailored treatments

AI facilitates personalized medicine by analyzing data from specific patient populations (Alowais et al., 2023). Whether you’re working in oncology or infectious disease, this kind of precision medicine can lead to better results for your patients.

Limitations and challenges of using AI in drug discovery

As promising as AI is, it comes with limitations that are important to understand.

Data limitations

AI needs high-quality data to be effective, but biological data isn’t always consistent or complete. If your data is biased or incomplete, AI models might make inaccurate predictions, which could compromise outcomes.

Integration with traditional methods

AI isn’t here to replace your lab work. It’s here to support it. Drug discovery still depends on experimental validation, and integrating AI with traditional research methods takes careful coordination.

Explainability and transparency

Many AI models work like “black boxes,” meaning their decision-making processes aren't always clear. In a regulated field like healthcare, this lack of transparency can make it more challenging to obtain approvals or establish trust.

Ethical and regulatory challenges

When using AI, it is essential to ensure compliance with privacy laws, fairness in data use, and patient safety. Regulatory bodies require extensive validation before approving any AI-assisted drug candidates (Mennella et al., 2024).

Overreliance on AI

AI is a tool, not a replacement for your expertise. Overdependence can lead to overlooking critical biological details or introducing errors. Your role in reviewing, validating, and interpreting AI outputs remains essential.

Conclusion

Artificial intelligence technologies are enabling faster, more accurate, and cost-effective drug discovery. From target identification to personalized medicine, it allows you to streamline your work and deliver better outcomes to patients.

When used wisely, AI becomes a powerful partner in your mission to innovate and improve healthcare.

But AI isn’t a one-size-fits-all solution. It still relies on solid data, thoughtful integration with traditional methods, and human oversight. When used wisely, AI becomes a powerful partner in your mission to innovate and improve healthcare.

As these tools continue to evolve, so will your opportunities to create safer, more effective treatments, making AI an investment not just in technology, but in better care.

References

Alowais, S. A., Alghamdi, S. S., Alsuhebany, N., Alqahtani, T., Alshaya, A., Almohareb, S. N., Aldairem, A., Alrashed, M., Saleh, K. B., Badreldin, H. A., Yami, A., Harbi, S. A., & Albekairy, A. M. (2023). Revolutionizing healthcare: The role of artificial intelligence in clinical practice. BMC Medical Education, 23(1), Article [if applicable]. https://doi.org/10.1186/s12909-023-04698-z

Chopra, H., Annu, Shin, D. K., Munjal, K., Choudhary, P., Dhama, K., & Emran, T. B. (2023). Revolutionizing clinical trials: The role of AI in accelerating medical breakthroughs. International Journal of Surgery, 109(12). https://doi.org/10.1097/js9.0000000000000705

Desai, D., Kantliwala, S., Vybhavi, J., Ravi, R., Patel, H., & Patel, J. (2024). Review of AlphaFold 3: Transformative advances in drug design and therapeutics. Cureus, 16(7), Article 63646. https://doi.org/10.7759/cureus.63646

Javid, S., Rahmanulla, A., Ahmed, M. G., Sultana, R., & Prashantha Kumar, B. R. (2025). Machine learning & deep learning tools in pharmaceutical sciences: A comprehensive review. Intelligent Pharmacy. https://doi.org/10.1016/j.ipha.2024.11.003

Jiang, Q., Yang, S., He, S., & Li, F. (2024). AI drug discovery tools and analysis technology: New methods aid in studying the compatibility of Traditional Chinese Medicine. Pharmacological Research - Modern Chinese Medicine, 14, Article 100566. https://doi.org/10.1016/j.prmcm.2024.100566

Mennella, C., Maniscalco, U., Pietro, G. D., & Esposito, M. (2024). Ethical and regulatory challenges of AI technologies in healthcare: A narrative review. Heliyon, 10(4), Article e26297. https://doi.org/10.1016/j.heliyon.2024.e26297

Rehman, A. U., Li, M., Wu, B., Ali, Y., Rasheed, S., Shaheen, S., Liu, X., Luo, R., & Zhang, J. (2024). Role of artificial intelligence in revolutionizing drug discovery. Fundamental Research. https://doi.org/10.1016/j.fmre.2024.04.021

Tripathi, S., Augustin, A. I., Dunlop, A., Sukumaran, R., Dheer, S., Zavalny, A., Haslam, O., Austin, T., Donchez, J., Tripathi, P. K., & Kim, E. (2022). Recent advances and application of generative adversarial networks in drug discovery, development, and targeting. Artificial Intelligence in the Life Sciences, 2, Article 100045. https://doi.org/10.1016/j.ailsci.2022.100045

Vora, L. K., Gholap, A. D., Jetha, K., Thakur, R. R. S., Solanki, H. K., & Chavda, V. P. (2023). Artificial intelligence in pharmaceutical technology and drug delivery design. Pharmaceutics, 15(7), Article 1916. https://doi.org/10.3390/pharmaceutics15071916

Yadav, S., Singh, A., Singhal, R., & Yadav, J. P. (2024). Revolutionizing drug discovery: The impact of artificial intelligence on advancements in pharmacology and the pharmaceutical industry. Intelligent Pharmacy, 2(3), Article [if applicable]. https://doi.org/10.1016/j.ipha.2024.02.009